For a study, researchers sought to review the data from a cross-sectional survey conducted between 2008 and 2016 on 1,384 women who had undergone screening-related colonoscopies. To estimate the comparative risk of developing adenomatous polyps, serrated polyps, high-risk adenomatous polyps (HRAPs), and high-risk serrated polyps (HRSPs) related to pregnancy, menopausal status, and the use of Hormone replacement therapy (HRT) (duration and type), modified Poisson regression models with robust error variance were utilised. The results showed that the probability of getting an HRSP was considerably reduced in women who had used HRT for more than 6 years [risk ratios (RR): 0.53; 95% CI: 0.29-0.97]. The use of HRT that included progesterone either by itself or in combination with oestrogen was linked with a lower risk of developing an HRSP (relative risk (RR): 0.54; 95% CI: 0.30-0.95). This was the case regardless of the length of time that the HRT was used. The use of HRT with progesterone for more than 6 years was related to a decreased risk of acquiring an HRSP (relative risk (RR): 0.42; 95% CI: 0.17-1.04). There was no correlation between any of the investigated reproductive factors, including HRT, and the growth of adenomatous polyps or HRAPs. According to the findings of this research, long-term usage of hormone replacement therapy and treatments that included progesterone were linked to a lower risk of developing hormone-related breast and ovarian pathologies HRSPs. These findings might have repercussions for screening women for serrated polyps using a targeted approach.
- Business of Medicine
- Doctor’s Voice